PARP-inhibitors applied to BRCA1-null PDX models
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
Expression changes in BRCA1-deficient breast cancer PDX models treated with PARP-inhibitors.
应用场景：
创建时间：
2018-05-31
相关数据集
Transcriptome Analysis of Gene Expression involving C/EBPÃ and Olaparib Resistance
Poly(ADP-ribose) polymerase inhibitors (PARPi) are now widely used in treating ovarian cancer. However, PARPi resistance emerges gradually. To investigate the change of gene expression during the tran
NIAID Data Ecosystem70
RNAseq analysis of BRCA deficient tumors treated with saline, Nano-Talazoparib or Talazoparib. RNAseq analysis of BRCA deficient tumors treated with saline, Nano-Talazoparib or Talazoparib
We report the gene expression profile in BRCA deficient tumors after treatment with saline, nanoparticle-formulated Talazoparib and free Talazoparib Overall design: To study the regulation of gene exp
NIAID Data Ecosystem50
Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
Germline mutations in BRCA1 or BRCA2 exist in approximately 7% of patients diagnosed with breast cancer and are associated with defects in homologous recombination repair, which has led to the approva
NIAID Data Ecosystem30
DataSheet2_The Great Majority of Homologous Recombination Repair-Deficient Tumors Are Accounted for by Established Causes.xlsx
Background: Gene-agnostic genomic biomarkers were recently developed to identify homologous recombination deficiency (HRD) tumors that are likely to respond to treatment with PARP inhibitors. Two mach
NIAID Data Ecosystem70
Additional file 8 of MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
Additional file 8: Table S3. Detailed clinical characteristics of each enrolled HGSOC patients from Qilu hospital.
Figshare2024-02-14 更新30
